Reuters logo
BRIEF-Axovant announces negative topline results of intepirdine phase 3 mindset trial in Alzheimer's disease
September 26, 2017 / 11:23 AM / a month ago

BRIEF-Axovant announces negative topline results of intepirdine phase 3 mindset trial in Alzheimer's disease

Sept 26 (Reuters) - Axovant Sciences Ltd

* At 24 weeks, patients treated with 35 mg of intepirdine did not experience improvement in cognition

* Axovant Sciences - ‍announced that phase 3 mindset clinical trial of its investigational drug intepirdine did not meet its co-primary efficacy endpoints​

* Axovant Sciences Ltd - ‍in study, intepirdine was generally well tolerated​

* Axovant Sciences - ‍headway trial studying intepirdine in patients with dementia remains on track to report topline results at end of 2017​

* Axovant Sciences - ‍after 24 weeks of treatment, change from baseline in cognition was non-significantly improved in intepirdine arm versus placebo arm​

* Axovant Sciences Ltd - ‍there was essentially no difference between intepirdine and placebo arms in change from baseline in activities of daily living​

* Axovant Sciences - ‍headway trial studying intepirdine in patients with dementia with lewy bodies remains on track to report topline results at end of 2017​

* Axovant Sciences - ‍only endpoint in which any significant improvement was seen in intepirdine arm versus placebo arm was in first key secondary endpoint​

* Axovant Sciences Ltd - ‍company will work with investigators to conclude mindset open-label extension study​ Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below